Private equity’s $860 billion zombie company problem

PitchBook data cited in the article shows 33.8% of 13,509 U.S. PE-backed companies have been held for 5+ years, implying 4,500+ “zombie” companies. It estimates about $860B of zombified net asset value sits in U.S. PE funds older than 7 years, reflecting how post-ZIRP cheap leverage and peak-2020/21 buyout pricing are now hard to unwind as rates rose. The piece argues the situation is likely a drag on fundraising and exits, but not yet a systemic break—suggesting outcomes will be delayed exits and/or eventual bankruptcies/wind-downs.

Analysis

This is less a crash signal than a duration problem: the asset class is carrying stale marks, but the real economic damage is slower realization velocity and weaker recycling of capital. That directly pressures fee growth, carry conversion, and fundraising power at the public alt managers most dependent on exits and vintage-year monetization; the market is likely still underestimating how long higher financing costs can suppress realizations even without a wave of outright failures.

The second-order winners are not the obvious “distressed” names but platform acquirers, rescue-capital providers, and credit complexes that can earn spread while others are trapped. In public equities, the cleaner relative beneficiaries are permanent-capital credit franchises with less dependence on IPO/M&A windows; the cleaner losers are PE-heavy managers and investment banks with sponsor-fee sensitivity. Over 1-3 months, this is mostly an earnings-guidance story; over 6-18 months, the key variable is whether lower rates reopen sponsor-to-sponsor exits or instead reveal true credit impairment in the zombie stack.

The contrarian point: consensus may be too focused on systemic blowup. PE can prolong life far longer than public markets expect, so the tradable expression is probably relative underperformance, not a sector-wide collapse. What would falsify the thesis is a sustained rebound in sponsor exits, tighter leveraged-finance spreads, and visible improvement in DPI/realization rates across major alt managers within two quarters.

Key Decisions for Investors

• Short Carlyle (CG) or a PE-heavy basket vs long a more fee-stable financials proxy (XLF) for 1-3 months; thesis is slower realizations and weaker fundraising, not a balance-sheet event. Risk: faster-than-expected exit reopening or a sharp rate rally.
• Pair long Apollo (APO) or Ares (ARES) vs short CG into upcoming earnings/fundraising updates; the long leg has more permanent-capital/credit sensitivity and should be more resilient if exit markets stay shut. Watch for AUM growth and fee-related earnings as the falsifier.
• Buy modest downside protection on investment-bank proxies with sponsor revenue exposure, especially GS/MS, using 3-6 month puts on strength; this is a clean hedge if M&A/IPO windows stay muted. Cut if announced deal volume and ECM pipelines reaccelerate.
• Set an alert on leveraged-loan and CLO spread widening (especially CCC tranches); if spreads gap wider while default data stays benign, that is the first market-readable sign the zombie problem is moving from nuisance to credit event.